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Abstract Selenium is known to exert multiple beneficial effects
including anti-inflammatory actions. The aim of the study was to
evaluate the effects of selenium supplementation on gene expres-
sion levels of inflammatory cytokines and vascular endothelial
growth factor (VEGF) in women with gestational diabetes
(GDM). This randomized double-blind, placebo-controlled trial
was carried out among 40 subjects diagnosed with GDM aged
18–40 years old. Subjects were randomly allocated into two
groups to receive either 200 μg/day selenium supplements
(n = 20) or placebo (n = 20) for 6 weeks. Gene expression of
inflammatory cytokines and VEGF were assessed in lympho-
cytes of GDM women with RT-PCR method. Results of
RT-PCR indicated that after the 6-week intervention, compared
with the placebo, selenium supplementation downregulated gene
expression of tumor necrosis factor alpha (TNF-α) (P = 0.02)
and transforming growth factor beta (TGF-β) (P = 0.01), and
upregulated gene expression ofVEGF (P= 0.03) in lymphocytes
of patients with GDM. There was no statistically significant
change following supplementation with selenium on gene
expression of interleukin (IL)-1β and IL-8 in lymphocytes of
subjects with GDM. Selenium supplementation for 6 weeks in
women with GDM significantly decreased gene expression of
TNF-α and TGF-β, and significantly increased gene expression
of VEGF, but did not affect gene expression of IL-1β and IL-8.
Clinical trial registration number http://www.irct.ir:
IRCT201612045623N95.
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Introduction
Gestational diabetes mellitus (GDM) is defined as impaired
glucose intolerance and insulin resistance with onset or recog-
nition during pregnancy [1]. GDM affects up to 200,000 de-
liveries in USA each year [2]. In a meta-analysis study, the
prevalence of GDM in Iran was reported 3.41% (the highest
and the lowest prevalence rates were 18.6 and 1.3%, respec-
tively) [3]. Pregnancy and GDM are associated with an in-
crease in inflammatory cytokines including tumor necrosis
factor-α (TNF-α) and interleukin (IL)-6, which in turn may
play an important role in development of pregnancy compli-
cations [4]. In addition, few studies have reported that the
vascular endothelial growth factor (VEGF) placental expres-
sion and fetal cord levels in GDM were significantly lower
than normal, which in turn may contribute to the pathogenic
vascular defects [5, 6].
Selenium as a functional component of the glutathione per-
oxidase (GPx) is an inhibitor of hydrogen peroxide in addition
to lipid hydroperoxides [7]. Furthermore, selenium exerts reg-
ulatory functions on cellular growth, transformation, and reg-
ulation of the rate of transcription of various genes [8]. In a
study, selenium deficiency in rats increased the binding of
* Maryam Rahimi
me616us@yahoo.com
* Zatollah Asemi
asemi_r@yahoo.com
1 Endocrinology and Metabolism Research Center, Department of
Gynecology and Obstetrics, School of Medicine, Arak University of
Medical Sciences, Arak, Iran
2 Department of Gynecology and Obstetrics, School of Medicine,
Kashan University of Medical Sciences, Kashan, Iran
3 Research Center for Biochemistry and Nutrition in Metabolic
Diseases, Kashan University of Medical Sciences, Kashan, IR, Iran
4 Department of Gynecology and Obstetrics, School of Medicine, Iran
University of Medical Sciences, Tehran, Iran
Biol Trace Elem Res (2018) 181:199–206
DOI 10.1007/s12011-017-1045-8
liver nuclear proteins to DNA regulatory elements nuclear
factor kappa-light-chain-enhancer of activated B cells
(NF-κB) nuclear factor I, which activate transcription of many
pro-inflammatory genes in response to increased oxidative
stress [9]. In addition, data on the effects of selenium supple-
mentation on inflammatory cytokines are scarce and inconsis-
tent. We have previously shown that 200 μg/day selenium
supplementation in pregnant women with GDM for 6 weeks
decreased high-sensitivity C-reactive protein levels [10]. In
addition, selenium induced protective effects against
diabetes-induced brain and erythrocyte oxidative injuries in
diabetic rats through regulation of the antioxidant levels and
the production of inflammatory cytokines [11]. However, se-
lenium supplementation at dosage of 400 μg daily for 14 days
had no effect on pro-inflammatory cytokine levels in patients
undergoing hematopoietic stem cell transplantation [12].
The anti-inflammatory effect of selenium may be mediated
by decreased activation of Erk-MAP kinase pathway [13] and
switching the arachidonic acid pathway from the
pro-inflammatory prostaglandin E2 to anti-inflammatory
15d-PGJ2, which in turn inhibits NF-kB pathway [14].
According to our knowledge, data on the effects of selenium
supplementation on gene expression levels of inflammatory
cytokines and VEGF in patients with GDM are limited. The
aim of this study was to evaluate the effects of selenium sup-
plementation on gene expression levels of inflammatory cyto-
kines and VEGF in patients with GDM.
Subjects and Methods
Participants
The current, randomized, double-blind, placebo-controlled
clinical trial, registered in the Iranian website for registration
of clinical trials (http://www.irct.ir: IRCT201612045623N95),
was performed among 40womenwith GDM aged 18–40 years
without prior diabetes diagnosed based on the American
Diabetes Association guidelines [15] from November 2016 to
January 2017. The study was approved by the research ethics
committee of Arak University of Medical Sciences and written
informed consent was taken from all the study participants.
Exclusion criteria were taking selenium supplements before
the intervention, needing insulin therapy, placenta abruption,
pre-eclampsia, eclampsia, hypo and hyperthyroidism, and
smokers.
Study Design
Firstly, participants were randomly allocated into two groups to
receive either 200 μg selenium as selenium yeast free other sup-
plements such as zinc and copper (n = 20) or placebo (n= 20) per
day for 6 weeks. In the present study, we used the dosage of
200 μg/day selenium based on observed beneficial effects of
selenium supplementation on metabolic profiles in a previous
study in patients with GDM [10]. Selenium supplements and
placebo (cellulose) tablets were identical in shape and size and
manufactured by the Nature Made (California, USA) and Barij
Essence (Kashan, Iran), respectively. As edible cellulose is not
absorbed, this hypothesis supports that cellulose may have no
effect on gene expression. To assess the compliance, the remain-
ing supplements were counted and subtracted from the amount
of supplements provided to the participants. To increase the com-
pliance, all participants received short messages on their cell
phones every day to remind them about taking the tablets.
Randomization assignment was done using computer-generated
random numbers as blindness by a trained staff at the clinic.
Randomization and allocation were concealed from the re-
searchers and patients until the final analyses were completed.
In the randomized allocation sequence, enrolling subjects and
allocating them to interventions were conducted by a trained staff
at the clinic. Subjects were requested not to change their routine
physical activity or usual dietary intakes throughout the study
and not to consume any supplements other than the one provided
to them by the investigators as well as not to take any medica-
tions that might affect findings during the 6-weak intervention.
Dietary macro- and micronutrients intakes were determined
using the 3-day food records at weeks 0, 3, 5, and 6 of the
intervention. Modified Nutritionist-4 software program (First
Databank, San Bruno, CA) was used to determine macro- and
micronutrient intakes. Physical activity was described as meta-
bolic equivalents in hours per day [16].
Assessment of Anthropometric Measures
Weight and height of women were determined using a stan-
dard scale (Seca, Hamburg, Germany) in a fasting status at
baseline and after 6 weeks intervention. Body mass index
(BMI) was calculated as weight in kilogram divided by height
in meters squared.
Assessment of Outcomes
In our study, gene expression of TNF-αwas considered as the
primary outcome and gene expression of IL-1β, IL-8,
transforming growth factor beta (TGF-β) and VEGF were
considered as the secondary outcomes. As IL-8 is a key me-
diator associated with inflammation where it plays a key role
in neutrophil recruitment and neutrophil degranulation [17],
we selected it instead of other cytokines. In addition, IL-8
secretion is increased by oxidant stress, which thereby cause
the recruitment of inflammatory cells and induces a further
elevation in biomarkers of oxidant stress, making it a key
parameter in localized inflammation [18].
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Isolation of Lymphocyte
At baseline and after the 6-week intervention, 10 mL fasting
blood samples was collected in the anticoagulant ethylenedi-
aminetetraacetic acid tubes. Then, lymphocytes were extracted
from blood samples of subjects with GDM at the Arak refer-
ence laboratory, Arak, Iran, using 50% percoll solution (Sigma-
Aldrich, Dorset, UK) by centrifugation for 20 min and
3000 rpm at 4 °C. Thus, for preparing a stock isotonic percoll
solution, osmolity of the solution was adjusted by adding 1 part
of 10 × concentrated cell culture medium into the 9 parts of
percoll [19]. Osmolality of the stock solution was controlled by
osmometer model 3300 (LabX, EI Cajon, USA) [19]. Solution
of stock isotonic percoll was diluted by adding normal cell
culture medium [19]. The cells of lymphocytes which were at
the interface of percoll and serumwere removed using a pasteur
pipette and washed a few times with phosphate buffer saline
[19]. Samples were taken for cell count and viability testing by
trypan blue, RNA, and DNA extraction [19].
Total RNA Extraction
To RNA extraction, the RNX-plus kit Cat. No. RN7713C
(Cinnacolon, Tehran, Iran) was used. Total RNAwas isolated
from all samples according to the recommended protocol by
the manufacture. After preparation of homogenate, the cells
powder was harvested and resuspended in 1ml of RNAX-plus
reagent in a clean RNase-free tube. After incubation for 5 min
at room temperature, the sample was pipetted and subsequent-
ly treated with addition of 200 μl of chloroform. The mixture
was incubated at room temperature for 5 min after shaking
rigorously for 15 s [19]. The mixture was centrifuged at
12,000g for 15 min and the aqueous phase containing the
RNA was transferred to a clean RNase-free tube. The total
RNA was precipitated at room temperature for 15 min. The
pellet including total RNAwas washed using 75% ethanol and
centrifuge at 7500g for 8 min. After drying ethanol, the RNA
pellet resuspended in 50 μl or less of TE buffer. The concen-
tration of total RNA was calculated based on OD 260/280
ration measurements as a means to means to address purity
of RNA [19]. To confirm the integrity of extracted RNA, it
was electrophoresed. RNA suspension was frozen in −20 °C
until complementary DNA (cDNA) making. Following the
extraction of the total RNAs from each sample, RNA quanti-
fication was performed by UV spectrophotometer. Each sam-
ples’OD 260/280 ratio between 1.7 and 2.1 was intended that
shows no contamination with both protein and DNA [19].
First Strand cDNA Synthesis Procedure
The first strand cDNA synthesis can be performed as an indi-
vidual reaction or as a series of parallel reactions with different
RNA templates [19]. Therefore, the reaction mixture can be
provided by merging reagents individually or a master mix
can be prepared all of the components except template
RNA. Depending on the structure of RNA templates, separate
steps for RNA denaturation and primer annealing may im-
prove RT-PCR results. The isolated RNA was reverse tran-
scribed to cDNA library using the Moloney murine leukemia
virus reverse transcriptase. Reverse transcription was per-
formed with random primers.
Gene Expression
Gene expression of TNF-α, TGF-β, IL-1β, IL-8, and VEGF
were evaluated by quantitative RT-PCR in lymphocytes, using
the LightCycler technology LightCycler® 480 System (Roche
Diagnostics, Rotkreuz, Switzerland) with SYBR green detection
and Amplicon Kit (Table 1). Glyceraldehyde-3-phosphate dehy-
drogenase primers were applied as housekeeping gene. As tem-
plate, approximately 50 ng cDNAwas applied in a quantitative
real-time RT-PCR, and the signals were detected using a
real-time PCR system. All reactions were run in duplicates. To
design primers, Primer Express software (Applied Biosystems,
Foster City) and Beacon designer software (Takaposizt, Tehran,
Iran) were used. Relative transcription values were calculated by
the method of Pffafi or 2-ΔΔCT. Starting material obtained from
different individuals usually varies in tissue mass or cell number,
RNA integrity or quantity, or experimental treatment.
Statistical Analyses
To confirm whether the study variables had normally distrib-
uted or not, we used the Kolmogrov-Smirnov test. To detect
changes in anthropometric measures as well as in macro- and
micronutrient dietary intakes between the two groups, we used
independent samples t test. To establish the effects of selenium
administration on gene expression related to inflammation and
VEGF, we used independent samples t test. All data were
expressed as mean ± standard deviation. Analysis of covari-
ance using general linear models assessed differences between
groups at the end of the study after adjustment for baseline
values of variables, age, and BMI at baseline. The P value of
<0.05 were considered statistically significant. All statistical
analyses used the Statistical Package for Social Science ver-
sion 18 (SPSS Inc., Chicago, Illinois, USA).
Results
As demonstrated in the study flow diagram (Fig. 1), during the
enrollment phase of the study, we invited 50 subjects with GDM;
however, 10 participants were excluded from the study because
of not meeting inclusion criteria. Finally, 40 participants [placebo
(n = 20) and selenium (n = 20)] completed the trial.
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Mean age, height, weight, and BMI at baseline and after the
6-week treatment were not statistically different between the
two groups (Table 2).
Based on a 3-day dietary records obtained at baseline,
end-of-intervention and throughout the trial, we found no sig-
nificant change between the two groups in terms of dietary
intakes of energy, carbohydrates, proteins, fats, saturated fatty
acids, polyunsaturated fatty acids, monounsaturated fatty
acids, cholesterol, total dietary fiber, magnesium, selenium,
and vitamins C, E, and A (data not shown).
Quantitative results of RT-PCR demonstrated that com-
pared with the placebo, selenium supplementation downregu-
lated gene expression of TNF-α (0.92 ± 0.24-fold reduction
vs. 1.08 ± 0.17-fold increase, P = 0.02) in lymphocytes of
patients with GDM (Fig. 2). When we adjusted the analysis
for baseline values of TNF-α, maternal age, and baseline
BMI, our findings did not alter (data not shown).
Comparedwith the placebo, selenium supplementation down-
regulated gene expression of TGF-β (0.90 ± 0.26-fold reduction
vs. 1.07 ± 0.14-fold increase, P = 0.01) in lymphocytes of pa-
tients with GDM (Fig.3). Adjustments for baseline values of
TGF-β, maternal age, and baseline BMI did not affect our find-
ings (data not shown).
We did see no significant effect of selenium supplementation
on gene expression of IL-1β (P = 0.35) and IL-8 (P = 0.75) in
lymphocytes of subjects with GDM (Figs.4 and 5).
Taking selenium, compared with the placebo, upregulated
gene expression of VEGF (1.08 ± 0.27-fold increase vs.
0.91 ± 0.19-fold reduction, P = 0.03) in lymphocytes of sub-
jects with GDM (Fig.6). When we adjusted the analysis for
baseline values of VEGF, maternal age, and baseline BMI, our
findings did not alter (data not shown).
Discussion
To our knowledge, this research is the first to evaluate effects
of selenium supplementation on gene expression related to
inflammatory factors and VEGF in lymphocytes among
GDM women. We found that taking selenium supplements
for 6 weeks among GDM women had beneficial effects on
gene expression of TNF-α, TGF-β, and VEGF in lympho-
cytes among GDM women.
This study demonstrated that selenium supplementation in
patients with GDM for 6 weeks downregulated gene expression
TNF-α and TGF-β in lymphocytes but did not affect IL-1β and
IL-8. In a study by Bi et al. [20], it was observed that gene
expression of TNF-α, IL-1β, and IL-6 significantly decreased.
In addition, adding selenium to macrophages led to a significant
decrease in the LPS-induced expression of two important
Table 1 Specific primers used
for real-time quantitative PCR Gene Primer Product size
(bp)
Annealing
temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
TNF-α F: GTCAACCTCCTCTCTGCCAT
R: CCAAAGTAGACCTGCCCAGA
188 52
TGF-β F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
IL-1β F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
VEGF F: CTTCTGAGTTGCCCAGGAGA 216 54
R: CTCACACACACACAACCAGG
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; IL-1β, interleukin-1β; IL-8, interleukin-8; TNF-α, tumor
necrosis factor alpha; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor
Table 2 General characteristics of study participants
Placebo group
(n = 20)
Selenium group
(n = 20)
Pa
Age (y) 28.3 ± 4.0 29.1 ± 2.9 0.48
Height (cm) 160.6 ± 4.4 160.3 ± 3.1 0.80
Weight at study baseline (kg) 70.7 ± 8.3 71.5 ± 5.9 0.69
Weight at end-of-trial (kg) 72.8 ± 8.4 73.7 ± 5.9 0.66
Weight change (kg) 2.1 ± 0.5 2.2 ± 0.6 0.68
BMI at study baseline (kg/m2) 27.4 ± 2.8 27.8 ± 2.4 0.58
BMI at end-of-trial (kg/m2) 28.2 ± 2.9 28.7 ± 2.5 0.56
BMI change (kg/m2) 0.8 ± 0.2 0.9 ± 0.2 0.61
Data are means ± standard deviation
a Obtained from independent t test
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pro-inflammatory genes, including cyclooxygenase-2 and
TNF-α via the inhibition of MAP kinase pathways [13]. Also,
selenium-enriched probiotics significantly decreased the expres-
sion of TGF-β1 and inflammation-related gene in rats [21].
Furthermore, taking selenium 200 μg/day or selenium 800 μg/
day among elderly men either statistically or marginally signifi-
cantly decreased inflammatory cytokines [22]. However, we pre-
viously shown that selenium supplementation at a dosage of
200 μg/day among patients with diabetic nephropathy did not
affect TGF-β levels [23]. Previous studies have documented that
TNF-α and interleukin family to stimulate system A amino acid
transporter activity in cultured primary human trophoblast cells
of the term placenta [24] as well as in hepatocyte cell lines [25].
Moreover, placental system A activity is positively associated
with birth weight in women across a range of body mass indices
[26], suggesting a relationship between maternal adiposity, sys-
temic inflammation, placental nutrient transport, and birth size.
The system A amino acid transporter, also known as the
Na+-dependent neutral amino acid transporter, mediates transport
of small neutral amino acids such as alanine, serine, glutamine,
and glycine in a Na+-coupled fashion [27]. Inflammatory cyto-
kines especially TNF-α also involve in the pathogenesis of insu-
lin resistance in human pregnancy [28]. Few studies have report-
ed that there is an increase in pro-inflammatory cytokines, includ-
ing TNF-α and a decrease in anti-inflammatory cytokines, such
as adiponectin, in the plasma of women with GDM [4, 29].
Placenta and adipose tissues from subjects with GDM released
higher amounts of TNF-α in response to high glucose than that
from normal pregnant women [30]. These pro-inflammatory cy-
tokines may be a pathophysiological link between GDM and
future type 2 diabetes andmetabolic syndrome, including cardio-
vascular diseases [31, 32]. In addition, increased TNF-α during
late pregnancy was inversely correlated with the insulin sensitiv-
ity [33]. Pro-inflammatory cytokines also play a key role in
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Fig. 3 Effect of the 6-week supplementation with selenium or placebo on
expression ratio of TGF-β gene in lymphocytes of GDM women
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Fig. 2 Effect of the 6-week supplementation with selenium or placebo on
expression ratio of TNF-α gene in lymphocytes of GDM women
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regulating placental transport of nutrients including fatty acids
[34] and amino acids [24]. On the other hand, TGF-β levels in
diabetes were evaluated in animal models and human studies
[35, 36]. It was reported that rats with streptozotocin-induced
diabetes had higher TGF-β expression levels during the first
day of hyperglycemia [37]. There are numerous studies indicat-
ing the importance of TGF-β in inflammatory conditions, insulin
resistance, angiogenesis, and atherosclerosis. It is shown that
TGF-β potently stimulates monocyte chemotaxis and endotheli-
al transmigration and promotes smooth muscle cell proliferation
and migration by up-regulating platelet-derived growth factor
gene expression [38]. Furthermore, TGF-β up-regulates tissue
factor gene expression levels in adipocytes [39]. Another impor-
tant finding is that TGF-β acts to elevate blood pressure by
increasing the levels of vasoactive mediators and by changing
vessel wall architecture to increase peripheral resistance [40].
Also, TGF-β inhibits the production of nitric oxide and stimu-
lates the expression of endothelin-1 secreted by endothelial cells
[41], which in turn is associated with pulmonary hypertension
[42]. TGF-β also stimulates renin release from glomerular cells,
elevating blood pressure through the generation of angiotensin II
[43]. These studies provide direct evidence for the role of TGF-β
in the development of vascular complications in conditions asso-
ciated with metabolic syndrome such as GDM. Hence,
understanding the molecular mechanisms by which cytokines
modulate nutrient transport may aid in the development of ther-
apeutic strategies to reduce the incidence of fetal overgrowth in
GDM pregnancies, and thus reduce the development of adult
metabolic diseases. The decreased activation of Erk-MAP kinase
pathway by selenium intake may be associated with decreased
inflammation [13]. In addition, selenium supplementation may
decrease the production of inflammatory markers by inhibiting
the MAP kinase pathways [44]. Selenium intake may also atten-
uate inflammation through inhibiting NF-κB and increasing pro-
duction of GPx [13]. It must be kept inmind that circulatingmilk
fat globule-epidermal growth factor 8 (MFG-E8) concentrations
are dramatically elevated during pregnancy and are significantly
higher in GDMcomparedwith normal pregnancy [45].MFG-E8
levels are significantly associated with increased levels of
TNF-α, fasting glucose and insulin resistance [45].
Additionally, among pro-inflammatory cytokines, TNF-α has
been demonstrated to be the most significant predictor of
pregnancy-induced insulin resistance and bemore highly synthe-
sized and released from the placenta compared with IL-6 or IL-8
[46]. In another study, Christian et al. [47] comprehensivelymea-
sured pro-inflammatory cytokines IL-6, IL-8, TNF-α, and IL-1β
in a total of 57 women of normal BMI, overweight and obese
women in the first, second, and third trimesters as well as 4–
6 weeks post-partum. In normal pregnant women, levels of
IL-6 and TNF-α increased at each visit and postpartum, while
IL-8 and IL-1β decreased from the first to the third trimester [47].
All of these may be explained as beneficial effects of selenium
supplementation on gene expression of TNF-α compared with
IL-1β and IL-6. Nonetheless, further studies are needed to con-
firm our findings.
The current study showed that selenium supplementation
in GDM women for 6 weeks upregulated gene expression of
VEGF in lymphocytes. Few researchers have previously
shown that VEGF placental expression and fetal cord levels
in patients with GDMwere significantly lower than normal [5,
VEGF
0.0
0.5
1.0
1.5 P=0.03
Placebo Selenium
F
ol
d 
in
cr
ea
se
Fig. 6 Effect of the 6-week supplementation with selenium or placebo on
expression ratio of VEGF gene in lymphocytes of GDM women. GDM
gestational diabetes, IL-1β interleukin-1β, IL-8 interleukin-8, TNF-α
tumor necrosis factor alpha, TGF-β transforming growth factor beta,
VEGF vascular endothelial growth factor
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Fig. 4 Effect of the 6-week supplementation with selenium or placebo on
expression ratio of IL-1β gene in lymphocytes of GDM women
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Fig. 5 Effect of the 6-week supplementation with selenium or placebo on
expression ratio of IL-8 gene in lymphocytes of GDM women
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6]. Data on the effects of selenium supplementation on VEGF
are limited. In a study by Bajpai et al. [48], it was observed
that the administration of sodium selenite in diabetic mice
significantly increased VEGF levels on day 7 and 13.
However, on day 13, the elevation in VEGF levels was less
than that of at day 7. However, supplementation with antiox-
idant micronutrients including selenium, vitamins C and E,
β-carotene, zinc, and glutamine in trauma patients with disor-
ders in wound healing did not affect VEGF levels [49]. High
blood glucose concentrations especially poorly controlled in
GDM trigger severe hypoxia/ischemia, which in turn result in
reduction of hypercapillarization, and therefore fetal hypoxia
as a result of maternal diabetes does not stimulate VEGF ex-
pression in the third trimester [50]. The reduced levels of
VEGF might lead to the increased gap junction activity lead-
ing to increased passage of apoptotic and pro-inflammatory
[48]. VEGF is vital in promoting vascular endothelial cell
growth and in increasing the number of vessels and capillaries,
which in turn ensuring the adequate supply of nutrients to the
fetus via classical feedback mechanism [51]. Some studies
have documented VEGF as a key angiogenetic factor in both
physiological and pathological conditions [52]. As the placen-
ta is one of main sources of VEGF during pregnancy, de-
creased expression of VEGF in placenta in patients with
GDM may contribute to the pathogenic vascular defects
which could be observed on the histological examination
[6]. Therefore, increased VEGF expression levels in our study
may support angiogenic remodeling of the early vessels, stim-
ulating the formation of a capillary network within the mes-
enchymal villus core [53].
Overall, selenium supplementation in women with GDM
for 6 weeks significantly decreased gene expression of
TNF-α and TGF-β and significantly increased gene expres-
sion of VEGF in lymphocytes but did not affect gene expres-
sion of IL-1β and IL-8. This suggests selenium supplemen-
tation may confer advantageous therapeutic potential for pa-
tients with GDM.
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